ADHD Patch Helps Investors Focus on Shire

Filed under: Stocks to Buy

The Food and Drug Administration (FDA) recently gave Shire Plc (SHPGY) shareholders something to smile about when it approved Daytrana for treating patients between 13 and 17 years who suffer from Attention Deficit Hyperactivity Disorder (ADHD).



Daytrana is the only ADHD treatment that is available in a transdermal patch, which delivers methylphenidate through the skin into the bloodstream. It is already approved for use by patients between 6 and 12 years.



With this announcement, Shire -- which licensed Daytrana from Noven Pharmaceuticals -- stands to gain market share and increase revenues.

Continue reading ADHD Patch Helps Investors Focus on Shire

ADHD Patch Helps Investors Focus on Shire originally appeared on BloggingStocks on Wed, 07 Jul 2010 18:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments
















Attention Deficit Hyperactivity Disorder - Daytrana - Shire plc - Mental health - BloggingStocks

Full story at http://www.pheedcontent.com/click.phdo?i=b416c7b780b73c4649455b81ff057d09